ADORA2A and renal cell carcinoma: Adenosine mediates TME immunosuppression of immune cells via ADORA2A, and in addition, drugs targeting ADORA2A have entered phase I clinical trials for immunotherapy of renal cell carcinoma (Fong et al., 2020; Feng et al., 2022).